Tucked into another incredibly busy news week was Eli Lilly’s announcement that their weight loss pill, Orforglipron, passed a key weight loss trial. Earlier, there was concern that a large percentage of participants who took the daily pill during a trial stopped, and the overall average percent of weight loss of 12.4% over 18 months … Read More